News Can Keytruda beat Opdivo to full UK access in lung cancer? A decisive moment in lung cancer treatment is nearing
News NICE proposals could cut wait for specialist treatments and ... Technologies for very rare conditions will also be automatically funded.
Views & Analysis NICE and NHS England unveil ‘fast-track’ and affordability s... NHS England will be able to control cost impact of NICE decisions more directly.
News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
Views & Analysis International benchmarking and NICE Is NICE willing to change, or is it inflexible? It is being pressed to compare itself to other HTA organisations.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
